Merck expands Hyderabad technology centre

For MSD, the economics are straightforward. Drug development is becoming more data-intensive, more regulated and more expensive, and companies are looking to widen their talent base without giving up control over core intellectual property. India offers a deep engineering pool and lower operating costs than the US or Europe, while Hyderabad has become a preferred location because it combines pharma manufacturing, software capability and policy support. That makes the city useful not just for back-office work, but for higher-value functions tied to product development and operational resilience.

The expansion also fits Merck’s broader cost-and-capital strategy. In its latest 10-Q, the company said it would keep hiring in strategic growth areas while reducing its global real-estate footprint and continuing to optimize its manufacturing network. It also disclosed sharply higher R&D spending this year, reflecting the industry-wide push to secure new growth after years of pressure on margins and looming patent cliffs. Moving more digital work into Hyderabad helps Merck preserve flexibility as it expands research spending elsewhere.

Investors are likely to read the move as supportive, but not transformative on its own. The bull case is that a larger technology centre improves execution, speeds up digitalization and helps the company manage rising development complexity without a proportional rise in US labor costs. The bear case is that these centers can become another layer of spending if AI and cloud investments fail to translate into faster pipelines, better launches or lower operating costs.

The announcement also reinforces Hyderabad’s standing as a magnet for global capability centres. Local officials have said the city is attracting dozens of new centers and benefiting from a broader wave of life-sciences and technology investment. That matters for India’s economy because it supports high-skilled employment, export-oriented services and deeper integration into global pharmaceutical supply chains.

What to watch next is whether MSD turns the centre into a wider operating model for Merck across Asia and whether other drugmakers follow with similar expansions. If they do, Hyderabad’s rise as a digital life-sciences hub could become more than a local jobs story and instead mark a structural shift in how big pharma organises research and technology work.